Today: 23 March 2026
Subscribe
Browse Category

NASDAQ:CLSD 24 November 2025

CLSD Stock Crashes Over 60% Today as Clearside Biomedical Files for Chapter 11 Bankruptcy

CLSD Stock Crashes Over 60% Today as Clearside Biomedical Files for Chapter 11 Bankruptcy

Clearside Biomedical filed for Chapter 11 bankruptcy Monday and will seek a court-supervised sale of its assets. CLSD stock plunged nearly 68% to around $0.88 by late afternoon, hitting a new 52-week low after closing at $2.69 Friday. Trading volume spiked to roughly 12 times normal levels. The company cited “substantial doubt” about its ability to continue as a going concern in its latest quarterly filing.
24 November 2025
··

Stock Market Today

  • Novo Nordisk vs. Structure Therapeutics: Weighing Top Obesity Stocks
    March 23, 2026, 12:42 PM EDT. Novo Nordisk (NVO) leads in the GLP-1 obesity treatment market with its semaglutide drugs Ozempic, Rybelsus, and Wegovy, holding a 52% market share as of June 2025. The Danish pharma giant focuses on expanding indications and manufacturing capacity amid strong demand but faces stiff competition from Eli Lilly's tirzepatide and challenges from compounded GLP-1 rivals. Novo recently cut its 2025 sales guidance due to slower obesity market adoption. Structure Therapeutics (GPCR), a clinical-stage biotech, is developing multiple obesity drugs but lacks NVO's commercial scale. Investors must choose between NVO's established market presence and GPCR's unproven potential. Novo also undergoes leadership changes amid shareholder-board tensions, adding governance risk to its profile.
Go toTop